Review
Pathology
Sulieman Ibraheem Shelash Al-Hawary, Ebraheem Abdu Musad Saleh, Nodirjon Akhmetovich Mamajanov, Nataliya S. Gilmanova, Hashem O. Alsaab, Adel Alghamdi, Shakeel Ahmed Ansari, Ahmed Hussien Radie Alawady, Ali Hashiem Alsaalamy, Ahmed Jaber Ibrahim
Summary: According to the International Agency for Research on Cancer, breast cancer is more common than lung cancer globally. By 2040, mortality from breast cancer will rise by 50% and 40%, respectively. Despite advances in chemotherapy, endocrine therapy, and HER2-targeted therapy, breast cancer metastases and recurrences remain challenging to treat.
PATHOLOGY RESEARCH AND PRACTICE
(2023)
Review
Oncology
J. Tobias, E. Garner-Spitzer, M. Drinic, U. Wiedermann
Summary: Immunotherapy has revolutionized cancer treatment, with a focus on breast cancer. Traditional treatment methods have limitations, but tumor vaccines may offer a potential solution. This review discusses peptide-based Her-2 / neu vaccines and their evaluation in clinical settings.
Article
Oncology
Kevin T. Lynch, Gabriella C. Squeo, William J. Kane, Max O. Meneveau, Gina Petroni, Walter C. Olson, Kimberly A. Chianese-Bullock, Craig L. Slingluff, Eugene F. Foley, Charles M. Friel
Summary: Checkpoint-blockade therapy (CBT) is approved for select colorectal cancer (CRC) patients, but additional immunotherapeutic options are needed. Vaccination with carcinoembryonic antigen (CEA) and Her2/neu (Her2) peptides was found to be well tolerated and immunogenic in participants with advanced CRC. Adverse events were mainly mild, with 70% of participants showing immune response to the peptides and a median overall survival of 16 months. Further study is warranted to assess the clinical benefits of vaccination in advanced CRC.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Pharmacology & Pharmacy
Nastaran Barati, Fatemeh Mosaffa, Atefeh Razazan, Ali Badiee, Javad Behravan, Amin Reza Nikpoor, Seyed Mousa Motavallihaghi, Mahmoud Reza Jaafari
Summary: The study focuses on developing a nanoliposomal vaccine for HER2-overexpressing breast cancer to evaluate its immunotherapeutic effects. The findings demonstrate that the formulation is capable of eliciting CD8(+) and CD4(+) responses, inducing the synthesis of cytokines.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2022)
Article
Oncology
Hester A. Doyle, Renelle J. Gee, Tyler D. Masters, Christian R. Gee, Carmen J. Booth, Elizabeth Peterson-Roth, Raymond A. Koski, Stuart C. Helfand, Lauren Price, Deborah Bascombe, Dorothy Jackson, Rita Ho, Gerald R. Post, Mark J. Mamula
Summary: In an open-label phase I/II study, companion dogs with spontaneous tumors overexpressing EGFR were immunized with a specific peptide vaccine, leading to the production of antibodies with similar efficacy to monoclonal therapies cetuximab and trastuzumab. These antibodies bound both canine and human EGFR on tumor cells, inhibited EGFR signaling, and suppressed tumor growth in vitro. The data supports the idea of enhancing anti-tumor immunity with vaccine therapy, which may be used in combination with other immune modifying therapies such as checkpoint inhibitors.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Hye Yeon Koo, Su-Min Jeong, Mi Hee Cho, Sohyun Chun, Dong Wook Shin, Jinsung Park
Summary: Aspirin and metformin use may be associated with lower prostate cancer incidence and mortality, while statins are not associated with either.
SCIENTIFIC REPORTS
(2021)
Article
Immunology
Sofie Kirial Mork, Per Kongsted, Marie Christine Wulff Westergaard, Benedetta Albieri, Joachim Stoltenborg Granhoj, Marco Donia, Evelina Martinenaite, Morten Orebo Holmstroem, Kasper Madsen, Anders H. Kverneland, Julie Westerlin Kjeldsen, Rikke Boedker Holmstroem, Cathrine Lund Lorentzen, Nis Norgaard, Lars Vibe Andreasen, Grith Kroyer Wood, Dennis Christensen, Michael Schantz Klausen, Sine Reker Hadrup, Per Thor Straten, Mads Hald Andersen, Inge Marie Svane
Summary: This study evaluated the tolerability and safety of a vaccine using Bcl-XL-peptide and CAF((R))09b as an adjuvant in patients with hormone-sensitive prostate cancer. The optimal route of administration and vaccine immunogenicity were also assessed. The vaccine was found to be feasible and safe, and it was able to induce immune responses. IP administration led to earlier and stronger vaccine-specific immune responses compared to IM administration.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Yihan Zhou
Summary: Constituting 15 to 20% of breast cancer cases, the triple-negative subtype lacks effective hormone-associated therapies. A more powerful immunotherapeutic vaccination incorporating HER2/neu antigens has shown promising results in clinical trials, especially in the triple-negative population. The combination of HER2/neu-based vaccines with GM-CSF immunoadjuvants and targeted drugs has the potential to further enhance the efficacy of breast cancer treatment.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Masanori Noguchi, Kiyohide Fujimoto, Gaku Arai, Hiroji Uemura, Katsuyoshi Hashine, Hiroaki Matsumoto, Satoshi Fukasawa, Yasuo Kohjimoto, Hideomi Nakatsu, Atsushi Takenaka, Masato Fujisawa, Hirotsugu Uemura, Seiji Naito, Shin Egawa, Hiroyuki Fujimoto, Shiro Hinotsu, Kyogo Itoh
Summary: This study investigated the impact of personalized peptide vaccination (PPV) on overall survival (OS) in HLA-A24-positive patients with castration-resistant prostate cancer (CRPC) who failed docetaxel chemotherapy. The results showed that PPV did not prolong OS overall, but subgroup analysis revealed survival benefits in patients with a lower proportion of neutrophils or a higher proportion of lymphocytes at baseline.
Article
Oncology
Muhammad Luqman Nordin, Abdin Shakirin Mohamad Norpi, Pei Yuen Ng, Khatijah Yusoff, Nadiah Abu, Kue Peng Lim, Fazren Azmi
Summary: The role of vaccination has been expanded in the management of HER2/neu-positive breast cancer, with effective vaccines needing to induce both humoral and cellular immune responses. A multi-epitope peptide vaccine including B-cell epitope was found to be superior in inhibiting tumor growth and prolonging survival in animal models. This highlights the importance of incorporating B-cell epitopes in cancer vaccine design.
Article
Oncology
Hemanth K. Potluri, Tun L. Ng, Michael A. Newton, Douglas G. McNeel
Summary: Antibody responses to off-target cancer-associated proteins may not necessarily indicate antigen spread, especially in vaccine strategies that use GM-CSF as an adjuvant. Evaluating T cell responses to non-target antigens is a preferred approach for detecting immune-mediated antigen spread following immunotherapies.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Joshua Tobias, Mirjana Drinic, Sandra Hoegler, Katharina Ambroz, Karin Baier, Petra Kodajova, Erwin Tomasich, Anna S. Berghoff, Anna Schmid, Erika Garner-Spitzer, Lukas Kenner, Michael Kundi, Christoph C. Zielinski, Ursula Wiedermann
Summary: The combination of Her-2/neu vaccine and multi-peptide vaccine can reduce lung metastases and may prevent tumor recurrence and spread. Additionally, combination therapy targeting PD-L1 may result in complete remission of metastases.
TRANSLATIONAL ONCOLOGY
(2022)
Article
Engineering, Biomedical
Kyoung Sub Kim, Sanghee Lee, Kun Na, You Han Bae
Summary: This study describes a strategy using antigen and adjuvant encapsulated dendritic cell-targeted nanoparticles for immune activation in the small intestinal lymphatic system to inhibit melanoma development. Oral delivery of the nanoparticles enhances dendritic cell maturation and induces cancer-specific T helper type 1 and type 2 responses in the blood. Repeated oral administration of the nanoparticles increases the population of immune cells and completely prevents melanoma development.
ADVANCED HEALTHCARE MATERIALS
(2022)
Review
Immunology
Rania Bouzeyen, Babak Javid
Summary: Tuberculosis is a deadly bacterial infection and drug resistance poses a threat to successful treatment. Therapeutic vaccination, as a new treatment modality, holds potential as a useful adjunct therapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Patrick M. McCarthy, G. Travis Clifton, Timothy J. Vreeland, Alexandra M. Adams, Anne E. O'Shea, George E. Peoples
Summary: HER2 is a prevalent growth factor in malignancies, with over-expression linked to poor survival. The novel AE37 vaccine, based on HER2, shows potential in breast and prostate cancer clinical trials. Future trials may expand the use of AE37 in treating other HER2-expressing malignancies.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2021)